Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial
The lung immune prognostic index (LIPI) is proposed to differentiate prognosis and treatment benefit from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC). There is minimal information on the predictive importance with first-line, combination ICI approaches. In post...
Main Authors: | Ashley M. Hopkins, Ganessan Kichenadasse, Ahmad Y. Abuhelwa, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/5/1176 |
Similar Items
-
Reply to Auclin et al. Comment on “Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. <i>Cancers</i> 2021, <i>13</i>, 1176”
by: Ashley M. Hopkins, et al.
Published: (2021-07-01) -
Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01) -
Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
by: Nobutaka Kataoka, et al.
Published: (2020-09-01) -
Clinical case of long-term use of atezolizumab and bevacizumab in the first-line treatment of recurrence of non-small cell lung cancer
by: O. A. Rozonova, et al.
Published: (2020-07-01) -
Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration
by: Takamasa Hotta, et al.
Published: (2021-03-01)